Integrated Diagnostics Holdings plc (IDHC) Earnings Call Transcripts

Integrated Diagnostics Holdings plc's Latest Earnings Call - Q1 FY2026

Integrated Diagnostics Holdings plc (IDHC:GB) reported strong Q1 2026 results, with revenue growth of 31% year-on-year, reaching EGP 2.1 billion. This growth was driven by a 22% increase in test volumes and a 1% rise in average revenue per test. Net profit surged 78% to EGP 437 million, with an adjusted net profit margin improving to 14.1%. Management maintained guidance for 2026, projecting SAR 10 billion in revenue with a 43% gross profit margin and around 30% EBITDA margin. The stock could be positively impacted by the robust growth in Egypt and the promising expansion in Saudi Arabia.

Reported metrics

Guidance from management

Management maintained guidance for 2026, projecting SAR 10 billion in revenue with a 43% gross profit margin and around 30% EBITDA margin. Plans to expand to 10 branches in Saudi Arabia by year-end were confirmed.

What management said

Okay. Ahmed, KSA revenue will be SAR 18 million for the budget. Our budget for 2026 for the first question will be around SAR 10 billion, with margins of 43% for gross profit and around 30% for the EBITDA.

And I mean, we are still -- we have increased 7% overall, and we maintain the flexibility to increase the prices. If anything happens regarding the depreciation of the Egyptian Pound or anything that we need to do in terms of price increase, we still have the flexibility to do it during the year. .

What analysts pressed on

Analysts expressed concerns about the impact of geopolitical tensions on costs and inventory. Questions were raised about the slower branch rollout in Saudi Arabia and the potential need for further price increases due to currency volatility.

Main topics on the call

• Revenue Growth — IDH achieved a 31% revenue growth year-on-year in Q1 2026, reaching EGP 2.1 billion, driven by a 22% increase in test volumes and a 1% rise in average revenue per test.
• Egypt Market Performance — Egypt's revenues increased 35% year-on-year to EGP 1.8 billion, contributing 85% of total revenues. This was supported by a 22% increase in test volumes and a 10% rise in average revenue per test.
• Saudi Arabia Expansion — Saudi Arabia showed strong progress with Biolab generating SAR 2.2 million in revenues, a 171% year-on-year growth. Plans to expand to 10 branches by year-end were discussed.
• Profitability — Net profit increased 78% year-on-year to EGP 437 million. Gross profit margin was stable at 38.9%, while EBITDA margin was 29.5%, reflecting temporary pressures.

Read the full Integrated Diagnostics Holdings plc transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 19 Integrated Diagnostics Holdings plc earnings call transcripts on record, spanning June 3, 2020 to June 1, 2026. Based on this history, Integrated Diagnostics Holdings plc reports semi-annually. The most recent call on file is dated June 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IDHC

Exchange

LSE

Country

GB

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

19

First call

June 3, 2020

Most recent

June 1, 2026

Reporting cadence

semi-annually